These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 18303482)

  • 1. Cell signaling modifiers in prostate cancer.
    Chen FL; Armstrong AJ; George DJ
    Cancer J; 2008; 14(1):40-5. PubMed ID: 18303482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
    Majumder PK; Febbo PG; Bikoff R; Berger R; Xue Q; McMahon LM; Manola J; Brugarolas J; McDonnell TJ; Golub TR; Loda M; Lane HA; Sellers WR
    Nat Med; 2004 Jun; 10(6):594-601. PubMed ID: 15156201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular target therapies in endometrial cancer: from the basic research to the clinic.
    Gadducci A; Tana R; Cosio S; Fanucchi A; Genazzani AR
    Gynecol Endocrinol; 2008 May; 24(5):239-49. PubMed ID: 18569027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
    Ziada A; Barqawi A; Glode LM; Varella-Garcia M; Crighton F; Majeski S; Rosenblum M; Kane M; Chen L; Crawford ED
    Prostate; 2004 Sep; 60(4):332-7. PubMed ID: 15264245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
    Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin: a new target in prostate cancer.
    Rai JS; Henley MJ; Ratan HL
    Urol Oncol; 2010; 28(2):134-8. PubMed ID: 19523861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the PI3K pathway: hope we can believe in?
    van der Heijden MS; Bernards R
    Clin Cancer Res; 2010 Jun; 16(12):3094-9. PubMed ID: 20400520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB receptors and signaling pathways in cancer.
    Hynes NE; MacDonald G
    Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of mTOR in cancer.
    Guertin DA; Sabatini DM
    Cancer Cell; 2007 Jul; 12(1):9-22. PubMed ID: 17613433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
    Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An expanding role for mTOR in cancer.
    Guertin DA; Sabatini DM
    Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
    Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Akt in cancer therapy.
    LoPiccolo J; Granville CA; Gills JJ; Dennis PA
    Anticancer Drugs; 2007 Sep; 18(8):861-74. PubMed ID: 17667591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Researchers may use cancer cell lines to identify target populations prior to clinical trials.
    Tuma RS
    J Natl Cancer Inst; 2006 Jun; 98(12):810-1. PubMed ID: 16788154
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.